COVID-19 vaccine candidates are garnering all the news these days, which is appropriate as they are our key to ending this pandemic. Earlier in this outbreak antiviral drugs received a good deal of attention, but they have proven less useful in curtailing infection. Less discussed are the many antiviral drug candidates that are in testing, …
An antiviral compound that blocks SARS-CoV-2 transmission in ferrets Read More »
Ralph Baric returns to TWiV to provide an update on the COVID-19 resurgence in the US, monoclonal antibodies, antiviral drugs, vaccines, immunity and reinfection, reopening schools, and what will happen this fall. Click arrow to playDownload TWiV 661 (70 MB .mp3, 116 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
Daniel Griffin provides a clinical report on COVID-19, then former FDA Chief of Staff to the Commissioner Denise Esposito joins us to explain the challenges in approving vaccines, antiviral drugs, and diagnostic tests during a pandemic, followed by answers to listener questions. Click arrow to playDownload TWiV 651 (98 MB .mp3, 164 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become …
From Georgia State University, Vincent speaks with Chris, Andrew, Priya, and Richard about their careers and their work on Ebolaviruses, rotavirus, and antiviral drug development. Click arrow to playDownload TWiV 636 (68 MB .mp3, 113 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
The 3,250,000 cases of COVID-19 and 233,000 deaths caused by SARS-CoV-2 (numbers as of this writing) could have largely been prevented. The viral outbreak could have been stopped in December in Wuhan had we had the foresight and financial support to develop antiviral drugs or vaccines. In the aftermath of the SARS-CoV pandemic of 2003, …
The SARS-CoV-2 pandemic could have been prevented Read More »
The common cold is an infection of the upper respiratory tract that may be caused by many different viruses, but most frequently by rhinoviruses. A compound that inhibits a cell enzyme and blocks rhinovirus replication has the potential to be developed into an antiviral drug (link to paper).
